Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s ...

As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal ...

Women in England are set to gain new, taxpayer-funded tests for endometriosis after NICE recommended them for regular use. | ...

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...

The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...

Despite decades of scientific progress and billions of dollars invested in oncology research, metastatic cancer remains overwhelmingly incurable. While many therapies can delay disease progression and ...

Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...